TY - JOUR
T1 - Influence of hyperlipidemia and its treatment on outcome in patients with peripheral arterial disease
AU - Ihnat, Daniel
AU - Tynan-Cuisiner, Gerlinda
AU - Mills, Joseph L.
PY - 2006/7
Y1 - 2006/7
N2 - Patients with peripheral artery disease (PAD), coronary heart disease, and diabetes mellitus have been shown conclusively to experience a 25% reduction in the rate of cardiovascular death, myocardial infarction, stroke and revascularization procedures by treatment with 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase inhibitors. Despite these findings, patients with PAD are frequently undertreated with respect to HMG-CoA reductase inhibitors, compared to patients with CHD. In addition, HMG-CoA reductase inhibitors produce numerous pleiotrophic effects that may reduce the incidence of restenosis after revascularization procedures.
AB - Patients with peripheral artery disease (PAD), coronary heart disease, and diabetes mellitus have been shown conclusively to experience a 25% reduction in the rate of cardiovascular death, myocardial infarction, stroke and revascularization procedures by treatment with 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase inhibitors. Despite these findings, patients with PAD are frequently undertreated with respect to HMG-CoA reductase inhibitors, compared to patients with CHD. In addition, HMG-CoA reductase inhibitors produce numerous pleiotrophic effects that may reduce the incidence of restenosis after revascularization procedures.
UR - http://www.scopus.com/inward/record.url?scp=33747406925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747406925&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:33747406925
SN - 1553-8036
VL - 3
SP - 317
EP - 321
JO - Vascular Disease Management
JF - Vascular Disease Management
IS - 4
ER -